Bibliography
- BOYLE JP, HONEYCUTT AA, NARAYAN KMV et al.: Projection of diabetes burden through 2050. Diabetes Care (2001) 24:1936-1940.
- BAILEY CJ, DAY C: Thiazolidinediones today. Br. J. Diab. Vasc. Dis. (2001) 1:7-13.
- OWENS DR: Thiazolidinediones: a pharmacological overview. Clin. Drug Investig. (2002) 22:485-505.
- ETGEN GJ, OLDMAN BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083-1087.
- YI P, HADDEN CE, ANNES WF et al.: The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist in mice, rats, and monkeys. Drug Metab. Dispos. (2007) 35(1):51-61.
- SAKAMOTO J, KIMURA H, MORIYAMA S et al.: A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur. J. Pharmacol. (2004) 495:17-26.
- MINOURA S, TAKESHITA M, ITA J et al.: Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. (2004) 494:273-281.
- TREADWAY JL, MENDYS P, HOOVER DJ: Glycogen phosphorylase inhibitors for treatment of Type 2 diabetes mellitus. Expert Opin. Investig. Drugs (2001) 10(3):439-454.
- MADSEN P, LING A, PLEWE M et al.: Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J. Med. Chem. (2002) 45:5755-5775.
- USTA MF, SANABRIA J, BIVALAQUA TJ, HELLSTROM WJ, SANABRIAV J: Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan). Int. J. Impot. Res. (2004) 16(1):73-77.
- STRUTHERS RS, CHEN TK, CAMPBELL B et al.: Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J. Clin. Endocrinol. Metab (2006) 91:3903-3907.
- ISHICHI Y, SASAKI M, SETOH M et al.: Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3- fluorobenzyl)piperidin-4-yl]- propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo- [3,2,1-ij]quinolin-4-one (TAK-802) and related compounds. Bioorg. Med. Chem. (2005) 13:1901-1911.
- COLCA JR, KLETZIEN RF: What has prevented the expansion of insulin sensitisers? Expert Opin. Investig. Drugs (2006) 15(3):205-210.
Website
- http://www.pharmaprojects.comThe Pharmaprojects database. Copyright © Informa UK Ltd (2007).